# Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

> **NCT03116529** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Maryland, Baltimore** · enrollment: 22 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **COMBINATION_PRODUCT:** Combination Radiation, Immunotherapy, Surgery

## Key facts

- **NCT ID:** NCT03116529
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-21
- **Primary completion:** 2024-06-21
- **Final completion:** 2024-06-21
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Limited Accrual
- **Last updated:** 2024-11-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03116529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03116529, "Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03116529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*